Company profile: Innate Pharma
1.1 - Company Overview
Company description
- Provider of first-in-class immunotherapy drug candidates for cancer and inflammatory diseases, specializing in novel monoclonal antibodies and NK cell engagers targeting innate immunity pathways. Pipeline includes ANKET; Lacutamab for cutaneous and peripheral T cell lymphomas; Monalizumab (anti-NKG2A) and CD39 with AstraZeneca for NSCLC and other solid tumors; CD123 and B7-H3 multi-specific ANKETs with Sanofi.
Products and services
- Monalizumab: An anti-NKG2A antibody co-developed with AstraZeneca for the treatment of non-small cell lung cancer, targeting NKG2A within pathways controlling innate immunity cell activation
- ANKET®: A proprietary platform that engineers multi-specific NK cell engager therapeutics to target and eliminate various tumor types, directing innate immunity activation against cancer
- Lacutamab: A proprietary antibody program developed for the treatment of advanced cutaneous T cell lymphomas and peripheral T cell lymphomas, focusing on targeted therapeutic activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Innate Pharma
Imbria
HQ: United States
Website
- Description: Provider of clinical-stage cardiometabolic therapies centered on ninerafaxstat, an investigational cardiac mitotrope designed to enhance cellular energy metabolism by increasing energy per molecule of oxygen consumed. Conducts Phase 2 trials: IMPROVE-HCM (non-obstructive HCM), IMPROVE-ISCHEMIA (stable angina/chronic coronary syndrome), and IMPROVE-DiCE (type 2 diabetes with HFpEF).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imbria company profile →
Cyclo Therapeutics
HQ: United States
Website
- Description: Provider of cyclodextrin-based therapeutics, including Trappsol® Cyclo™, a proprietary hydroxypropyl beta cyclodextrin formulation in clinical trials for Niemann-Pick Disease Type C1 and in a Phase 2b trial for early Alzheimer’s disease, leveraging data from an Expanded Access program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyclo Therapeutics company profile →
Alvotech
HQ: Iceland
Website
- Description: Provider of fully integrated biosimilar development and manufacturing, including monoclonal antibodies for immunology, oncology, and ophthalmology. Offers R&D and clinical services and worldwide commercial partnerships to expand access to biologic medicines. Employs single-use technology and Iceland’s renewable energy. Portfolio includes AVT02 (adalimumab) and AVT04 (ustekinumab), approved across multiple regions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alvotech company profile →
Amerita
HQ: United States
Website
- Description: Provider of specialty infusion services focused on delivering complex pharmaceutical products and clinical services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amerita company profile →
MediQuest Therapeutics
HQ: United States
Website
- Description: Provider of topical pharmaceutical solutions for inflammatory and infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MediQuest Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Innate Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Innate Pharma
2.2 - Growth funds investing in similar companies to Innate Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Innate Pharma
4.2 - Public trading comparable groups for Innate Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →